Skip to main content

Table 4 Adverse events and adverse drug reactions

From: An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome

  pAT AT gamma
N = 113 N = 108
AEs, n (%) 99 (87.6) 89 (82.4)
 AEs that led to death 22 (19.5) 10 (9.3)
 Other serious AEs 7 (6.2) 14 (13.0)
ADRs, n (%) 16 (14.2) 24 (22.2)
 ADRs that led to death 0 (0) 2 (1.9)
 Other serious ADRs 1 (0.9) 3 (2.8)
  1. ADR adverse drug reaction, AE adverse event, pAT plasma-derived antithrombin